Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a careful consideration of the study's findings, mentioning the trial's negative results on cardiovascular prevention despite improvements in symptoms, and addressing factors like treatment adherence and patient risk profiles, which indicates thoughtful engagement and recognition of its significance in sleep medicine and cardiovascular health.
Most discussions highlight the trial's findings that CPAP did not significantly prevent cardiovascular events, indicating general consensus or acknowledgment of these results.
Participants show moderate interest, with some expressing curiosity and highlighting the importance of improving therapies and identifying high-risk groups.
Many posts reference specific research details, such as trial results and compliance issues, showing an active engagement with the study data.
The discourse underscores the study's influence on clinical understanding and future research directions, emphasizing the need for better treatment strategies.
add on to Q14/A14 : Some studies define CPAP use as min of 4 hrs, -> patients are 1/2 night off CPAP but considered on CPAP which may contribute to conflicting results #HYPHIP @HyperAHA @DrDudenbostel @MaierLauren @CraigSteinback https://t.co/RoFp9zVmsP
Though it did not prevent CV events in pts with mod-severe #OSA +CVD, #CPAP significantly reduced #snoring and daytime #sleepiness and improved health-related QOL and mood. SAVE Trial. #PrimaryCareChat #SleepMatters https://t.co/Bz0goLEHM7
@SukhNijjer @DrVikasKapil - any thoughts on this trial? https://t.co/poK9Fa4RZZ
@ProfHayward ah I saw the SAVE trial found ppl in CPAP group report fewer days off work for health-related reasons, think that's a worthwhile outcome (if people like to go to work!) lol fairly tight confidence interval too. 0.82 (0.80-0.85) @AlexChaitoff @JeremySussman https://t.co/zjDTLeMTeX
@Dominik_Linz @AHAScience @ReenaMehra0203 @PrashSanders @SusanRedline @NancySRed @Vaish1986 @EP_mom1 @CircAHA @J_Hendriks1 @DavidDuncker @DrDave01 @escardio @CARIMMaastricht @adribaran @Elliott_AD @MDTolgaAksu @EmmaSvennberg @ChristianHeeger Interesting theory. But the major (Industry sponsored) SAVE trial showed no CV or other major benefit from treating OSA with CPAP? #awkward https://t.co/VScbf8eqTQ
@AbdTahrani @MichaelAlbertMD Exactly: https://t.co/Od4mn3g5mY
This week, John Mandrola MD discusses screening for valvular heart disease, the efficacy of multivitamins, and the role of CPAP in preventing cardiovascular events in sleep apnea patients. The insights highlight recent…
Hello, welcome to this episode dedicated to obstructive sleep apnea. Sleep apnea is not just snoring or fatigue; it's a serious medical condition impacting your health. Learn about its effects on the heart and how to…
CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea | New England Journal of Medicine https://t.co/0tKbAqIvVj
@H0B0_elite Snoring can be adaptive/protective to secure venous return while sleeping. Cardiac events, even death, from poor venous return during severe stress. CPAP doesn't provide cardiac protection contrary to common belief. Many allergy sx seem protective. https://t.co/NZ6xcIQVmn
「CPAPを3時間以上使用しても心血管イベントを予防できなかった。日中の眠気やQOLはCPAP利用群で有意に改善した。」 CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea NEJM September 8, 2016 R. Doug McEvoy, M.D.
@MohitHarshMD I’ll admit, I’m a little pessimistic about the benefits of CPAP. Clear benefit in daytime sleepiness. CV benefits seem less clear. But I do always address it. https://t.co/iLuEi70Wbs
En la charla del doctpr Malhotra recuerda el trabajo de NEJM de 2016 donde se concluye en ese entonces que para son necesarioñ mejores terapias y adherencia, identificar mejor pacientes de alto riesgo y mas inestigacion basica 2 https://t.co/AmUsvXJ5w1
RT @DrDudenbostel: add on to Q14/A14 : Some studies define CPAP use as min of 4 hrs, -> patients are 1/2 night off CPAP but considered on C…
RT @DrDudenbostel: add on to Q14/A14 : Some studies define CPAP use as min of 4 hrs, -> patients are 1/2 night off CPAP but considered on C…
RT @DrDudenbostel: add on to Q14/A14 : Some studies define CPAP use as min of 4 hrs, -> patients are 1/2 night off CPAP but considered on C…
add on to Q14/A14 : Some studies define CPAP use as min of 4 hrs, -> patients are 1/2 night off CPAP but considered on CPAP which may contribute to conflicting results #HYPHIP @HyperAHA @DrDudenbostel @MaierLauren @CraigSteinback https://t.co/RoFp9zVmsP
@bobepidemiology This is another multi centre study, trying to assess the benefits on cardiovascular events. When you read through the study, compliance to the treatment impacted effectiveness. https://t.co/X3hgLGelM9
@taipan168 There's a special irony in the fact that the only large trial of CPAP masks showed they don't work... "CPAP + usual care vs. usual care alone did not prevent cardiovascular events in patients with moderate-severe obstructive sleep apnea & CV disease" https://t.co/VScbf7XnRQ
@Dominik_Linz @AHAScience @ReenaMehra0203 @PrashSanders @SusanRedline @NancySRed @Vaish1986 @EP_mom1 @CircAHA @J_Hendriks1 @DavidDuncker @DrDave01 @escardio @CARIMMaastricht @adribaran @Elliott_AD @MDTolgaAksu @EmmaSvennberg @ChristianHeeger Interesting theory. But the major (Industry sponsored) SAVE trial showed no CV or other major benefit from treating OSA with CPAP? #awkward https://t.co/VScbf8eqTQ
@Carcos2 @KikeCimas y el clásico https://t.co/hAGrYxnOIL?
@AbdTahrani @MichaelAlbertMD Exactly: https://t.co/Od4mn3g5mY
@ProfHayward ah I saw the SAVE trial found ppl in CPAP group report fewer days off work for health-related reasons, think that's a worthwhile outcome (if people like to go to work!) lol fairly tight confidence interval too. 0.82 (0.80-0.85) @AlexChaitoff @JeremySussman https://t.co/zjDTLeMTeX
@MaxJordan_N @BenMazer Good questions, check out the SAVE trial NEJM https://t.co/NaQl7M1OON they tried to find the highest risk group to see mortality or composite CV event benefit. Unfortunately no difference.
RT @drandrewsharp: @SukhNijjer @DrVikasKapil - any thoughts on this trial? https://t.co/poK9Fa4RZZ
RT @drandrewsharp: @SukhNijjer @DrVikasKapil - any thoughts on this trial? https://t.co/poK9Fa4RZZ
@SukhNijjer @DrVikasKapil - any thoughts on this trial? https://t.co/poK9Fa4RZZ
@rafabravo Curioso resultado, en pacientes de muy alto riesgo CV. Quizá el tiempo medio de uso de CPAP (2,78 h/noche) puede influir. Pero en el análisis ajustado a cumplimiento tampoco parece afectar el resultado. Ya había datos que ponían en cuestión el beneficio CV https://t.co/KY0SxQTYPh
Though it did not prevent CV events in pts with mod-severe #OSA +CVD, #CPAP significantly reduced #snoring and daytime #sleepiness and improved health-related QOL and mood. SAVE Trial. #PrimaryCareChat #SleepMatters https://t.co/Bz0goLEHM7
@pcorrea78 @elespectador https://t.co/HR8jInihXm No sabía que no se podían enviar PDF por aquí, pero este es el link ya esta libre. https://t.co/b2WgVWbMJy
CPAPで心血管イベントを防ぐことはできませんぜ、って文献をクリティカルに読むことになった。 CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea | NEJM https://t.co/9NH8K9tzzW
TF
PC
AS
MN
PL
CB
CM
WF
ST
H
FR
GM
KC
RB
PJ
LG
AC
CC
P
坂P